ID   MAG_HUMAN               Reviewed;         626 AA.
AC   P20916; B7Z2E5; F5GYC0; Q15489; Q567S4;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   03-AUG-2022, entry version 207.
DE   RecName: Full=Myelin-associated glycoprotein;
DE   AltName: Full=Siglec-4a;
DE   Flags: Precursor;
GN   Name=MAG; Synonyms=GMA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2476987; DOI=10.1016/0006-291x(89)91145-5;
RA   Sato S., Fujita N., Kurihara T., Kuwano R., Sakimura K., Takahashi Y.,
RA   Miyatake T.;
RT   "cDNA cloning and amino acid sequence for human myelin-associated
RT   glycoprotein.";
RL   Biochem. Biophys. Res. Commun. 163:1473-1480(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=2479762; DOI=10.1002/jnr.490240203;
RA   Spagnol G., Williams M., Srinivasan J., Golier J., Bauer D., Lebo R.V.,
RA   Latov N.;
RT   "Molecular cloning of human myelin-associated glycoprotein.";
RL   J. Neurosci. Res. 24:137-142(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT MET-202.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 528-626 (ISOFORM 2), ALTERNATIVE SPLICING,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Brain {ECO:0000312|EMBL:CAA67055.1};
RX   PubMed=9495552; DOI=10.1016/s0169-328x(97)00254-4;
RA   Miescher G.C., Luetzelschwab R., Erne B., Ferracin F., Huber S.,
RA   Steck A.J.;
RT   "Reciprocal expression of myelin-associated glycoprotein splice variants in
RT   the adult human peripheral and central nervous systems.";
RL   Brain Res. Mol. Brain Res. 52:299-306(1997).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=6200494; DOI=10.1016/0165-5728(84)90039-0;
RA   Favilla J.T., Frail D.E., Palkovits C.G., Stoner G.L., Braun P.E.,
RA   Webster H.D.;
RT   "Myelin-associated glycoprotein (MAG) distribution in human central nervous
RT   tissue studied immunocytochemically with monoclonal antibody.";
RL   J. Neuroimmunol. 6:19-30(1984).
RN   [8]
RP   GLYCOSYLATION AT ASN-99; ASN-106; ASN-223; ASN-246; ASN-315; ASN-406;
RP   ASN-450 AND ASN-454, AND LACK OF GLYCOSYLATION AT ASN-332.
RX   PubMed=7505568; DOI=10.1006/bbrc.1993.2501;
RA   Burger D., Pidoux L., Steck A.J.;
RT   "Identification of the glycosylated sequons of human myelin-associated
RT   glycoprotein.";
RL   Biochem. Biophys. Res. Commun. 197:457-464(1993).
RN   [9]
RP   INTERACTION WITH RTN4R.
RX   PubMed=19052207; DOI=10.1523/jneurosci.3828-08.2008;
RA   Budel S., Padukkavidana T., Liu B.P., Feng Z., Hu F., Johnson S.,
RA   Lauren J., Park J.H., McGee A.W., Liao J., Stillman A., Kim J.E.,
RA   Yang B.Z., Sodi S., Gelernter J., Zhao H., Hisama F., Arnsten A.F.,
RA   Strittmatter S.M.;
RT   "Genetic variants of Nogo-66 receptor with possible association to
RT   schizophrenia block myelin inhibition of axon growth.";
RL   J. Neurosci. 28:13161-13172(2008).
RN   [10]
RP   INVOLVEMENT IN SPG75, AND VARIANT SPG75 GLY-430.
RX   PubMed=24482476; DOI=10.1126/science.1247363;
RA   Novarino G., Fenstermaker A.G., Zaki M.S., Hofree M., Silhavy J.L.,
RA   Heiberg A.D., Abdellateef M., Rosti B., Scott E., Mansour L., Masri A.,
RA   Kayserili H., Al-Aama J.Y., Abdel-Salam G.M., Karminejad A., Kara M.,
RA   Kara B., Bozorgmehri B., Ben-Omran T., Mojahedi F., Mahmoud I.G.,
RA   Bouslam N., Bouhouche A., Benomar A., Hanein S., Raymond L., Forlani S.,
RA   Mascaro M., Selim L., Shehata N., Al-Allawi N., Bindu P.S., Azam M.,
RA   Gunel M., Caglayan A., Bilguvar K., Tolun A., Issa M.Y., Schroth J.,
RA   Spencer E.G., Rosti R.O., Akizu N., Vaux K.K., Johansen A., Koh A.A.,
RA   Megahed H., Durr A., Brice A., Stevanin G., Gabriel S.B., Ideker T.,
RA   Gleeson J.G.;
RT   "Exome sequencing links corticospinal motor neuron disease to common
RT   neurodegenerative disorders.";
RL   Science 343:506-511(2014).
RN   [11]
RP   INVOLVEMENT IN SPG75, VARIANT SPG75 ARG-133, CHARACTERIZATION OF VARIANT
RP   SPG75 ARG-133, SUBCELLULAR LOCATION, TOPOLOGY, AND GLYCOSYLATION.
RX   PubMed=26179919; DOI=10.1093/brain/awv204;
RA   Lossos A., Elazar N., Lerer I., Schueler-Furman O., Fellig Y., Glick B.,
RA   Zimmerman B.E., Azulay H., Dotan S., Goldberg S., Gomori J.M., Ponger P.,
RA   Newman J.P., Marreed H., Steck A.J., Schaeren-Wiemers N., Mor N., Harel M.,
RA   Geiger T., Eshed-Eisenbach Y., Meiner V., Peles E.;
RT   "Myelin-associated glycoprotein gene mutation causes Pelizaeus-Merzbacher
RT   disease-like disorder.";
RL   Brain 138:2521-2536(2015).
RN   [12]
RP   VARIANT SPG75 HIS-118.
RX   PubMed=27606346; DOI=10.1002/acn3.329;
RA   Roda R.H., FitzGibbon E.J., Boucekkine H., Schindler A.B., Blackstone C.;
RT   "Neurologic syndrome associated with homozygous mutation at MAG sialic acid
RT   binding site.";
RL   Ann. Clin. Transl. Neurol. 3:650-654(2016).
CC   -!- FUNCTION: Adhesion molecule that mediates interactions between
CC       myelinating cells and neurons by binding to neuronal sialic acid-
CC       containing gangliosides and to the glycoproteins RTN4R and RTN4RL2 (By
CC       similarity). Not required for initial myelination, but seems to play a
CC       role in the maintenance of normal axon myelination. Protects
CC       motoneurons against apoptosis, also after injury; protection against
CC       apoptosis is probably mediated via interaction with neuronal RTN4R and
CC       RTN4RL2. Required to prevent degeneration of myelinated axons in
CC       adults; this probably depends on binding to gangliosides on the axon
CC       cell membrane (By similarity). Negative regulator of neurite outgrowth;
CC       in dorsal root ganglion neurons the inhibition is mediated primarily
CC       via binding to neuronal RTN4R or RTN4RL2 and to a lesser degree via
CC       binding to neuronal gangliosides. In cerebellar granule cells the
CC       inhibition is mediated primarily via binding to neuronal gangliosides.
CC       In sensory neurons, inhibition of neurite extension depends only
CC       partially on RTN4R, RTN4RL2 and gangliosides. Inhibits axon
CC       longitudinal growth (By similarity). Inhibits axon outgrowth by binding
CC       to RTN4R (By similarity). Preferentially binds to alpha-2,3-linked
CC       sialic acid. Binds ganglioside Gt1b (By similarity).
CC       {ECO:0000250|UniProtKB:P07722, ECO:0000250|UniProtKB:P20917}.
CC   -!- SUBUNIT: Monomer and homodimer (By similarity). Interacts (via the
CC       first three N-terminal Ig-like domains) with RTN4R and RTN4RL2 (By
CC       similarity). Interacts with RTN4R (PubMed:19052207). Interacts with
CC       isoform 2 of BSG (By similarity). {ECO:0000250|UniProtKB:P07722,
CC       ECO:0000250|UniProtKB:P20917, ECO:0000269|PubMed:19052207}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26179919};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:26179919}.
CC       Membrane raft {ECO:0000250|UniProtKB:P07722}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=L-MAG {ECO:0000303|PubMed:9495552};
CC         IsoId=P20916-1; Sequence=Displayed;
CC       Name=2; Synonyms=S-MAG {ECO:0000303|PubMed:9495552};
CC         IsoId=P20916-2; Sequence=VSP_042688;
CC       Name=3;
CC         IsoId=P20916-3; Sequence=VSP_045843;
CC   -!- TISSUE SPECIFICITY: Both isoform 1 and isoform 2 are detected in
CC       myelinated structures in the central and peripheral nervous system, in
CC       periaxonal myelin and at Schmidt-Lanterman incisures (PubMed:9495552,
CC       PubMed:6200494). Detected in optic nerve, in oligodendroglia and in
CC       periaxonal myelin sheaths (PubMed:6200494). Detected in compact myelin
CC       (at protein level) (PubMed:6200494). Both isoform 1 and isoform 2 are
CC       detected in the central and peripheral nervous system (PubMed:9495552).
CC       {ECO:0000269|PubMed:6200494, ECO:0000269|PubMed:9495552}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:26179919}.
CC   -!- PTM: Phosphorylated on tyrosine residues.
CC       {ECO:0000250|UniProtKB:P07722}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation.
CC       {ECO:0000250|UniProtKB:P20917}.
CC   -!- DISEASE: Spastic paraplegia 75, autosomal recessive (SPG75)
CC       [MIM:616680]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness and
CC       spasticity of the lower limbs. Rate of progression and the severity of
CC       symptoms are quite variable. Initial symptoms may include difficulty
CC       with balance, weakness and stiffness in the legs, muscle spasms, and
CC       dragging the toes when walking. In some forms of the disorder, bladder
CC       symptoms (such as incontinence) may appear, or the weakness and
CC       stiffness may spread to other parts of the body. SPG75 is characterized
CC       by onset in early childhood and is associated with mild to moderate
CC       cognitive impairment. {ECO:0000269|PubMed:24482476,
CC       ECO:0000269|PubMed:26179919, ECO:0000269|PubMed:27606346}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily. SIGLEC (sialic
CC       acid binding Ig-like lectin) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Siglec-4;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_271";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29273; AAA59545.1; -; mRNA.
DR   EMBL; AK294644; BAH11831.1; -; mRNA.
DR   EMBL; AC002132; AAB58805.1; -; Genomic_DNA.
DR   EMBL; AD000684; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC053347; AAH53347.1; -; mRNA.
DR   EMBL; BC093045; AAH93045.1; -; mRNA.
DR   EMBL; X98405; CAA67055.1; -; mRNA.
DR   CCDS; CCDS12455.1; -. [P20916-1]
DR   CCDS; CCDS12456.1; -. [P20916-2]
DR   CCDS; CCDS56090.1; -. [P20916-3]
DR   PIR; A61084; A61084.
DR   RefSeq; NP_001186145.1; NM_001199216.1. [P20916-3]
DR   RefSeq; NP_002352.1; NM_002361.3. [P20916-1]
DR   RefSeq; NP_542167.1; NM_080600.2. [P20916-2]
DR   AlphaFoldDB; P20916; -.
DR   SMR; P20916; -.
DR   BioGRID; 110273; 22.
DR   DIP; DIP-58523N; -.
DR   IntAct; P20916; 4.
DR   STRING; 9606.ENSP00000376048; -.
DR   BindingDB; P20916; -.
DR   ChEMBL; CHEMBL5807; -.
DR   GlyGen; P20916; 9 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P20916; -.
DR   PhosphoSitePlus; P20916; -.
DR   SwissPalm; P20916; -.
DR   BioMuta; MAG; -.
DR   DMDM; 126689; -.
DR   MassIVE; P20916; -.
DR   PaxDb; P20916; -.
DR   PeptideAtlas; P20916; -.
DR   PRIDE; P20916; -.
DR   ProteomicsDB; 24691; -.
DR   ProteomicsDB; 53823; -. [P20916-1]
DR   ProteomicsDB; 53824; -. [P20916-2]
DR   ABCD; P20916; 7 sequenced antibodies.
DR   Antibodypedia; 1364; 403 antibodies from 39 providers.
DR   DNASU; 4099; -.
DR   Ensembl; ENST00000361922.8; ENSP00000355234.4; ENSG00000105695.15. [P20916-2]
DR   Ensembl; ENST00000392213.8; ENSP00000376048.2; ENSG00000105695.15. [P20916-1]
DR   Ensembl; ENST00000537831.2; ENSP00000440695.1; ENSG00000105695.15. [P20916-3]
DR   GeneID; 4099; -.
DR   KEGG; hsa:4099; -.
DR   MANE-Select; ENST00000392213.8; ENSP00000376048.2; NM_002361.4; NP_002352.1.
DR   UCSC; uc002nyx.3; human. [P20916-1]
DR   CTD; 4099; -.
DR   DisGeNET; 4099; -.
DR   GeneCards; MAG; -.
DR   HGNC; HGNC:6783; MAG.
DR   HPA; ENSG00000105695; Tissue enriched (brain).
DR   MalaCards; MAG; -.
DR   MIM; 159460; gene.
DR   MIM; 616680; phenotype.
DR   neXtProt; NX_P20916; -.
DR   OpenTargets; ENSG00000105695; -.
DR   Orphanet; 459056; Autosomal recessive spastic paraplegia type 75.
DR   PharmGKB; PA30541; -.
DR   VEuPathDB; HostDB:ENSG00000105695; -.
DR   eggNOG; KOG4475; Eukaryota.
DR   GeneTree; ENSGT01040000240433; -.
DR   HOGENOM; CLU_020480_1_0_1; -.
DR   InParanoid; P20916; -.
DR   OMA; EIMDITP; -.
DR   PhylomeDB; P20916; -.
DR   TreeFam; TF332441; -.
DR   PathwayCommons; P20916; -.
DR   Reactome; R-HSA-193634; Axonal growth inhibition (RHOA activation).
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-9619665; EGR2 and SOX10-mediated initiation of Schwann cell myelination.
DR   SignaLink; P20916; -.
DR   SIGNOR; P20916; -.
DR   BioGRID-ORCS; 4099; 17 hits in 1073 CRISPR screens.
DR   ChiTaRS; MAG; human.
DR   GeneWiki; Myelin-associated_glycoprotein; -.
DR   GenomeRNAi; 4099; -.
DR   Pharos; P20916; Tchem.
DR   PRO; PR:P20916; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P20916; protein.
DR   Bgee; ENSG00000105695; Expressed in C1 segment of cervical spinal cord and 144 other tissues.
DR   ExpressionAtlas; P20916; baseline and differential.
DR   Genevisible; P20916; HS.
DR   GO; GO:0043218; C:compact myelin; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0097453; C:mesaxon; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IDA:UniProtKB.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; IEA:Ensembl.
DR   GO; GO:0033270; C:paranode region of axon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IEA:Ensembl.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:1905576; F:ganglioside GT1b binding; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0033691; F:sialic acid binding; ISS:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl.
DR   GO; GO:0031103; P:axon regeneration; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; ISS:UniProtKB.
DR   GO; GO:0098742; P:cell-cell adhesion via plasma-membrane adhesion molecules; ISS:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0032289; P:central nervous system myelin formation; IEA:Ensembl.
DR   GO; GO:0030517; P:negative regulation of axon extension; ISS:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0031643; P:positive regulation of myelination; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; HEP:UniProtKB.
DR   GO; GO:0019226; P:transmission of nerve impulse; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR013162; CD80_C2-set.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   Pfam; PF08205; C2-set_2; 1.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 2.
DR   SUPFAM; SSF48726; SSF48726; 5.
DR   PROSITE; PS50835; IG_LIKE; 3.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell adhesion; Cell membrane; Disease variant;
KW   Disulfide bond; Glycoprotein; Hereditary spastic paraplegia;
KW   Immunoglobulin domain; Lectin; Lipid-binding; Lipoprotein; Membrane;
KW   Neurodegeneration; Palmitate; Phosphoprotein; Reference proteome; Repeat;
KW   Signal; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..19
FT   CHAIN           20..626
FT                   /note="Myelin-associated glycoprotein"
FT                   /id="PRO_0000014856"
FT   TOPO_DOM        20..516
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        517..536
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        537..626
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          22..120
FT                   /note="Ig-like V-type"
FT   DOMAIN          139..237
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          241..325
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          327..412
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          413..508
FT                   /note="Ig-like C2-type 4"
FT   REGION          20..325
FT                   /note="Interaction with RTN4R and RTN4RL2"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   REGION          577..626
FT                   /note="Required for normal axon myelination in the central
FT                   nervous system"
FT                   /evidence="ECO:0000250|UniProtKB:P20917"
FT   REGION          582..608
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         65..67
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /evidence="ECO:0000250|UniProtKB:P20917"
FT   BINDING         118
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /evidence="ECO:0000250|UniProtKB:P20917"
FT   BINDING         124..128
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /evidence="ECO:0000250|UniProtKB:P20917"
FT   SITE            332
FT                   /note="Not glycosylated"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   MOD_RES         545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   MOD_RES         547
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   MOD_RES         549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   LIPID           531
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   CARBOHYD        99
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        106
FT                   /note="N-linked (GlcNAc...) asparagine; partial"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        223
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        246
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        315
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        406
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        450
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   CARBOHYD        454
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7505568"
FT   DISULFID        37..165
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        42..100
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        159..217
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        261..305
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        347..392
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        421..430
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        432..488
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         1..25
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045843"
FT   VAR_SEQ         574..626
FT                   /note="ERRLGSERRLLGLRGEPPELDLSYSHSDLGKRPTKDSYTLTEELAEYAEIRV
FT                   K -> KEVSTLESH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9495552"
FT                   /id="VSP_042688"
FT   VARIANT         118
FT                   /note="R -> H (in SPG75; unknown pathological significance;
FT                   dbSNP:rs762045079)"
FT                   /evidence="ECO:0000269|PubMed:27606346"
FT                   /id="VAR_077495"
FT   VARIANT         133
FT                   /note="S -> R (in SPG75; alters proper folding; impairs
FT                   N-glycosylation; retained in the endoplasmic reticulum;
FT                   increased proteasome-dependent degradation;
FT                   dbSNP:rs2301600)"
FT                   /evidence="ECO:0000269|PubMed:26179919"
FT                   /id="VAR_076224"
FT   VARIANT         202
FT                   /note="L -> M (in dbSNP:rs11084810)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_059399"
FT   VARIANT         430
FT                   /note="C -> G (in SPG75; unknown pathological significance;
FT                   dbSNP:rs587777229)"
FT                   /evidence="ECO:0000269|PubMed:24482476"
FT                   /id="VAR_076225"
FT   CONFLICT        614
FT                   /note="T -> S (in Ref. 2)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   626 AA;  69069 MW;  ED2D36B24F21CAAA CRC64;
     MIFLTALPLF WIMISASRGG HWGAWMPSSI SAFEGTCVSI PCRFDFPDEL RPAVVHGVWY
     FNSPYPKNYP PVVFKSRTQV VHESFQGRSR LLGDLGLRNC TLLLSNVSPE LGGKYYFRGD
     LGGYNQYTFS EHSVLDIVNT PNIVVPPEVV AGTEVEVSCM VPDNCPELRP ELSWLGHEGL
     GEPAVLGRLR EDEGTWVQVS LLHFVPTREA NGHRLGCQAS FPNTTLQFEG YASMDVKYPP
     VIVEMNSSVE AIEGSHVSLL CGADSNPPPL LTWMRDGTVL REAVAESLLL ELEEVTPAED
     GVYACLAENA YGQDNRTVGL SVMYAPWKPT VNGTMVAVEG ETVSILCSTQ SNPDPILTIF
     KEKQILSTVI YESELQLELP AVSPEDDGEY WCVAENQYGQ RATAFNLSVE FAPVLLLESH
     CAAARDTVQC LCVVKSNPEP SVAFELPSRN VTVNESEREF VYSERSGLVL TSILTLRGQA
     QAPPRVICTA RNLYGAKSLE LPFQGAHRLM WAKIGPVGAV VAFAILIAIV CYITQTRRKK
     NVTESPSFSA GDNPPVLFSS DFRISGAPEK YESERRLGSE RRLLGLRGEP PELDLSYSHS
     DLGKRPTKDS YTLTEELAEY AEIRVK
//
